CADM1/TSLC1 inactivation by promoter hypermethylation is a frequent event in colorectal carcinogenesis and correlates with late stages of the disease

International Journal of Cancer

Volumn 128, Issue 2, 2011, Pages 266-273

  Chen, Kequan ^a   Wang, Guanghai ^a   Peng, Liang ^a   Liu, Side ^a   Fu, Xiangsheng ^a   Zhou, Yu ^b   Yu, Haisheng ^a   Li, Aiming ^a   Li, Jing ^a   Zhang, Shaoheng ^a   Bai, Yang ^a   Zhang, Yali ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

CADM1 TSLC1; colorectal cancer; methylation; tumor suppressor gene

Indexed keywords

BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CELL ADHESION MOLECULE 1; GENOMIC DNA; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CLINICAL FEATURE; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADULT; AGED; CELL ADHESION MOLECULES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA METHYLATION; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 78649565293     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25356     Document Type: Article

References (23)

1. Iacopetta B, Grieu F, Li W, Ruszkiewicz A, Caruso M, Moore J, Watanabe G, Kawakami K,. APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer. Int J Cancer 2006; 119: 2272-8.
2. Baek YH, Chang E, Kim YJ, Kim BK, Sohn JH, Park DI,. Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis Colon Rectum 2009; 52: 1452-9.
3. Murakami Y, Nobukuni T, Tamura K, Maruyama T, Sekiya T, Arai Y, Gomyou H, Tanigami A, Ohki M, Cabin D, Frischmeyer P, Hunt P, et al,. Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci USA 1998; 95: 8153-8.
4. Murakami Y,. Functional cloning of a tumor suppressor gene, TSLC1, in human cell lung cancer. J Natl Cancer Inst 2002; 21: 6936-48.
5. Yamada D, Yoshida M, Williams YN, Fukami T, Kikuchi S, Masuda M, Maruyama T, Ohta T, Nakae D, Maekawa A, Kitamura T, Murakami Y,. Disruption of spermatogenic cell adhesion and male infertility in mice lacking TSLC1/IGSF, an immunoglobulin superfamily cell adhesion molecule. Mol Cell Biol 2006; 26: 3610-24.
6. Shingai T, Ikeda W, Kakunaga S, Morimoto K, Takekuni K, Itoh S, Satoh K, Takeuchi M, Imai T, Monden M, Takai Y,. Implications of nectin-like molecule-2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in cell-cell adhesion and transmembrane protein localization in epithelial cells. J Biol Chem 2003; 278: 35421-7.
7. Boles KS, Barchet W, Diacovo T, Cella M, Colonna M,. The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM. Blood 2005; 106: 779-86.
8. Sussan TE, Pletcher MT, Murakami Y, Reeves RH,. Tumor suppressor in lung cancer 1 (TSLC1) alters tumorigenic growth properties and gene expression. Mol Cancer 2005; 4: 28.
9. Mao X, Seidlitz E, Truant R, Hitt M, Ghosh HP,. Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. Oncogene 2004; 23: 5632-42.
10. Heller G, Fong KM, Girard L, Seidl S, End-Pfützenreuter A, Lang G, Gazdar AF, Minna JD, Zielinski CC, Zöchbauer-Müller S,. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene 2006; 25: 959-68.
11. Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y,. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. Int J Cancer 2003; 107: 53-9.
12. Honda T, Tamura G, Waki T, Jin Z, Sato K, Motoyama T, Kawata S, Kimura W, Nishizuka S, Murakami Y,. Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res 2002; 93: 857-60.
13. Ito T, Shimada Y, Hashimoto Y, Kaganoi J, Kan T, Watanabe G, Murakami Y, Imamura M,. Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res 2003; 63: 6320-6.
14. Tsujiuchi T, Sugata E, Masaoka T, Onishi M, Fujii H, Shimizu K, Honoki K,. Expression and DNA methylation patterns of Tslc1 and Dal-1 genes in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Cancer Sci 2007; 98: 943-8.
15. Shimizu K, Onishi M, Sugata E, Fujii H, Honoki K, Tsujiuchi T,. Aberrant DNA methylation of the 5′ upstream region of Tslc1 gene in hamster pancreatic tumors. Biochem Biophys Res Commun 2007; 353: 522-6.
16. Ando K, Ohira M, Ozaki T, Nakagawa A, Akazawa K, Suenaga Y, Nakamura Y, Koda T, Kamijo T, Murakami Y, Nakagawara A,. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation. Int J Cancer 2008; 123: 2087-94.
17. Mao X, Seidlitz E, Ghosh K, Murakami Y, Ghosh HP,. The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer. Cancer Res 2003; 63: 7979-85.
18. Kitamura Y, Kurosawa G, Tanaka M, Sumitomo M, Muramatsu C, Eguchi K, Akahori Y, Iba Y, Tsuda H, Sugiura M, Hattori Y, Kurosawa Y,. Frequent overexpression of CADM1/IGSF4 in lung adenocarcinoma. Biochem Biophys Res Commun 2009; 383: 480-4.
19. Borinstein SC, Conerly M, Dzieciatkowski S, Biswas S, Washington MK, Trobridge P, Henikoff S,. Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model. Mol Carcinog 2010; 49: 94-103.
20. Jansen M, Fukushima N, Rosty C, Walter K, Altink R, Heek TV, Hruban R, Offerhaus JG, Goggins M,. Aberrant methylation of the 5′ CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther 2002; 1: 293-6.
21. Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer W, Depisch D, Pirker R, Zielinski CC, et al,. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat 2007; 103: 283-91.
22. Goto T, Mizukami H, Shirahata A, Sakata M, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K,. Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer. Anticancer Res 2009; 29: 275-7.
23. Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS,. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol 2006; 210: 147-54.